General
Preferred name
DOXAPRAM
Synonyms
AHR-619 ()
Doxapram hydrochloride monohydrate ()
Doxapram HCl ()
Dopram ()
Doxapram hydrochloride ()
Doxapram H2OxHCl ()
Doxapram (hydrochloride hydrate) ()
Doxapram hydrochloride hydrate ()
NSC-760347 ()
NSC-170958 ()
Stimulexin ()
Docatone ()
doxapram ()
P&D ID
PD009963
CAS
7081-53-0
309-29-5
113-07-5
Tags
available
drug
Approved by
FDA
First approval
1965
Drug indication
panic disorder
Respiratory disease
Drug Status
vet_approved
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 ¦ÌM, 9 ¦ÌM, respectively.;Target: Potassium Channel;Doxapram is a respiratory stimulant. Doxapram (15-150 microM) also evoked 3H overflow in a concentration dependent manner, and doxapram-evoked release was inhibited by the Ca2+ channel blocker nifedipine (5 microM). Analysis of released tritiated compounds suggested that doxapram preferentially stimulated the release of dopamine. Our results indicate that the mechanism of action of doxapram shares similarities with that of hypoxia in the carotid body [1]. Doxapram (1-100 microM) caused rapid, reversible and dose-dependent inhibitions of K+ currents recorded in type I cells (IC50 approximately 13 microM). doxapram was also seen to directly inhibit Ca(2+)-independent K+ currents. Doxapram was a more potent inhibitor of the Ca(2+)-activated K+ currents recorded under control conditions. Doxapram (10 microM) was without effect on L-type Ca2+ channel currents recorded under conditions where K+ channel activity was minimized and was also without significant effect on K+ currents recorded in the neuronal cell line NG-108 15, suggesting a selective effect on carotid body type I cells. The effects of doxapram on type I cells show similarities to those of the physiological stimuli of the carotid body, suggesting that doxapram may share a similar mechanism of action in stimulating the intact organ [2].
DESCRIPTION Doxapram is an analeptic, ie it is a central nervous system stimulant.
Marketed formulations may contain doxapram hydrochloride (PubChem CID 64647). (GtoPdb)
PRICE 29
DESCRIPTION Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 ¦ÌM, 9 ¦ÌM, respectively.;Target: Potassium Channel;Doxapram is a respiratory stimulant. Doxapram (15-150 microM) also evoked 3H overflow in a concentration dependent manner, and doxapram-evoked release was inhibited by the Ca2+ channel blocker nifedipine (5 microM). Analysis of released tritiated compounds suggested that doxapram preferentially stimulated the release of dopamine. Our results indicate that the mechanism of action of doxapram shares similarities with that of hypoxia in the carotid body [1]. Doxapram (1-100 microM) caused rapid, reversible and dose-dependent inhibitions of K+ currents recorded in type I cells (IC50 approximately 13 microM). doxapram was also seen to directly inhibit Ca(2+)-independent K+ currents. Doxapram was a more potent inhibitor of the Ca(2+)-activated K+ currents recorded under control conditions. Doxapram (10 microM) was without effect on L-type Ca2+ channel currents recorded under conditions where K+ channel activity was minimized and was also without significant effect on K+ currents recorded in the neuronal cell line NG-108 15, suggesting a selective effect on carotid body type I cells. The effects of doxapram on type I cells show similarities to those of the physiological stimuli of the carotid body, suggesting that doxapram may share a similar mechanism of action in stimulating the intact organ [2].
DESCRIPTION Doxapram (Dopram) is a respiratory stimulant that inhibits TASK-1, TASK-3, and TASK-1/TASK-3 heterodimer channels and is used to study ventilatory failure caused by apnea of ??prematurity and exacerbation of chronic obstructive pulmonary disease.
PRICE 29
DESCRIPTION Doxapram hydrochloride hydrate (Doxapram HCl) effectively inhibits the function of TASK-1, TASK-3, and TASK-1/TASK-3 heterodimeric channels, displaying EC50 values of 410 nM, 37 ??M, and 9 ??M, respectively.
DESCRIPTION Doxapram is a short acting respiratory stimulant used to treat acute respiratory insufficiency in COPD patients. (Enamine Bioactive Compounds)
DESCRIPTION Doxapram is a respiratory stimulant with analeptic activity. Administered intravenously, doxapram stimulates an increase in tidal volume, and respiratory rate. Doxapram stimulates chemoreceptors in the carotid bodies of the carotid arteries, which in turn, stimulates the respiratory centre in the brain stem. It has been used as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. (BOC Sciences Bioactive Compounds)
DESCRIPTION Doxapram (Dopram) is a respiratory stimulant that inhibits TASK-1, TASK-3, and TASK-1/TASK-3 heterodimer channels and is used to study ventilatory failure caused by apnea of ​​prematurity and exacerbation of chronic obstructive pulmonary disease. (TargetMol Bioactive Compound Library)
DESCRIPTION Doxapram hydrochloride hydrate (Doxapram HCl) effectively inhibits the function of TASK-1, TASK-3, and TASK-1/TASK-3 heterodimeric channels, displaying EC50 values of 410 nM, 37 μM, and 9 μM, respectively. (TargetMol Bioactive Compound Library)
Compound Sets
26
BOC Sciences Bioactive Compounds
doxapram-cas-309-29-5-item-65721
Cayman Chemical Bioactives
23794
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL3989519
CHEMBL1754
ChEMBL Drugs
CHEMBL3989519
CHEMBL1754
DrugBank
DB00561
DrugBank Approved Drugs
DB00561
DrugCentral
953
DrugCentral Approved Drugs
953
DrugMAP
DMCYANK
DrugMAP Approved Drugs
DMCYANK
Enamine Bioactive Compounds
EBC-15038
Enamine BioReference Compounds
Guide to Pharmacology
7169
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1754
Mcule NIBR MoA Box Subset
MCULE-9853713128
MedChem Express Bioactive Compound Library
HY-B0551A
HY-B0551
NCATS Inxight Approved Drugs
94F3830Q73
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
doxapram-hcl
doxapram
TargetMol Bioactive Compound Library
T22315
T0038
The Spectrum Collection
External IDs
74
Properties
(calculated by RDKit )
Molecular Weight
378.23
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
2
cLogP
3.17
TPSA
32.78
Fraction CSP3
0.46
Chiral centers
1.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
chemoreceptor agonist
Target
Potassium channel subfamily K member 3
Potassium channel subfamily K member 9
Potassium Channel
TASK-1
TASK-1/TASK-3 heterodimeric
TASK-3
Member status
member
Therapeutic Class
Central Nervous System Stimulants
Pathway
Membrane Transporter/Ion Channel
Solubility
Soluble in DMSO, not in water.
Source data